Download PDF
Z Gastroenterol 2020; 58(12): 1209-1232
DOI: 10.1055/a-1296-3494
Übersicht

Aktualisierung der Colitis ulcerosa Leitlinie 2020

Torsten Kucharzik
1   Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg
,
Axel Dignaß
2   Medizinische Klinik 1, Agaplesion Markus Krankenhaus, Frankfurt/Main, Frankfurt am Main
,
Britta Siegmund
3   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Um dem Konzept der sogenannten „living guidelines“ Rechnung zu tragen, findet in jährlichen Abständen eine Überarbeitung der 2018 publizierten Colitis-ulcerosa-Leitlinie statt. Hintergrund des Konzepts ist der Wunsch, eine hohe Aktualität der Empfehlungen zu gewährleisten und neue diagnostische und therapeutische Aspekte, die nach Publikation der Leitlinie aufgetreten sind, zu berücksichtigen. Seit der letzten Aktualisierung der Leitlinie im Herbst 2019 hat die Steuergruppe als wesentliche Neuerung die Studiendaten zu Ustekinumab bei Colitis ulcerosa identifiziert, die im Herbst 2019 zur Zulassung der Substanz bei der Colitis ulcerosa mit mittel- bis hochgradiger Entzündungsaktivität und Versagen einer konventionellen Therapie geführt haben. Ustekinumab ist ein monoklonaler Antikörper, der gegen die p40-Untereinheit von Interleukin-12 und -23 gerichtet ist und der bereits eine gute Wirksamkeit und Verträglichkeit bei Patienten mit Morbus Crohn gezeigt hat. Das der Zulassung zugrunde liegende UNIFI-Studienprogramm konnte nun eine signifikante Überlegenheit gegenüber Placebo sowohl in der Induktions- als auch in der Erhaltungstherapie bei Patienten mit mittel- bis hochgradiger Entzündungsaktivität nachweisen [1]. Subanalysen der UNIFI-Studie konnten zeigen, dass bereits 2 Wochen nach Beginn der Induktionstherapie eine Reduktion der Stuhlfrequenz und der Blutbeimengungen sowie eine Reduktion von Calprotectin zu beobachten sind. Kürzlich konnte auch eine gute Langzeitwirkung von Ustekinumab nach 2 Jahren mit geringem Wirkverlust gezeigt werden [2]. Die bisherigen Real-World-Erfahrungen bei Patienten mit Colitis ulcerosa [3] sowie Studiendaten aus der Therapie von CED-Patienten und Daten aus dem PSOLAR-Register bei Psoriasis konnten bisher keine relevanten Signale für unerwünschte Nebenwirkungen, insbesondere das vermehrte Auftreten schwerer Infektionen, kardiovaskulärer Nebenwirkungen oder Hinweise auf Malignität identifizieren [4] [5].



Publication History

Article published online:
01 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381: 1201-1214
    CrossrefPubMedGoogle Scholar
  • 2 Sands BE, Sandborn W, Panaccione R. et al. Efficacy and safety of ustekinumab for ulcerative colitis through 2 years: UNIFI long-term extension. UEGW; 2019: LB01
    PubMedGoogle Scholar
  • 3 Amiot A, Filippi J, Abitbol V. et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther 2020; 51: 1039-1046
    CrossrefPubMedGoogle Scholar
  • 4 Papp K, Gottlieb AB, Naldi L. et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015; 14: 706-714
    PubMedGoogle Scholar
  • 5 Sandborn WJ, Feagan BG, Danese S. et al. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis 2020; DOI: 10.1093/ibd/izaa236.
    CrossrefPubMedGoogle Scholar
  • 6 Sands BE, Peyrin-Biroulet L, Loftus Jr EV. et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019; 381: 1215-1226
    CrossrefPubMedGoogle Scholar
  • 7 Bonovas S, Lytras T, Nikolopoulos G. et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454-465
    CrossrefPubMedGoogle Scholar
  • 8 Singh S, Fumery M, Sandborn WJ. et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 162-175
    CrossrefPubMedGoogle Scholar
  • 9 Singh S, Murad MH, Fumery M. et al. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020; 18: 2179-2191 e6
    CrossrefPubMedGoogle Scholar
  • 10 Wang Y, Parker CE, Bhanji T. et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4: CD000543
    PubMedGoogle Scholar
  • 11 Ford AC, Achkar JP, Khan KJ. et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-616
    CrossrefPubMedGoogle Scholar
  • 12 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544
    PubMedGoogle Scholar
  • 13 Dignass AU, Bokemeyer B, Adamek H. et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-769
    CrossrefPubMedGoogle Scholar
  • 14 Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18: 1785-1794
    CrossrefPubMedGoogle Scholar
  • 15 Gordon GL, Zakko S, Murthy U. et al. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. J Clin Gastroenterol 2016; 50: 318-325
    CrossrefPubMedGoogle Scholar
  • 16 Kamm MA, Lichtenstein GR, Sandborn WJ. et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902
    CrossrefPubMedGoogle Scholar
  • 17 Kruis W, Jonaitis L, Pokrotnieks J. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-322
    CrossrefPubMedGoogle Scholar
  • 18 Sandborn WJ, Korzenik J, Lashner B. et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-1296, 1296 e1–3
    CrossrefPubMedGoogle Scholar
  • 19 Heyman MB, Kierkus J, Spenard J. et al. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis 2010; 16: 1931-1939
    CrossrefPubMedGoogle Scholar
  • 20 Kobayashi K, Hirai F, Naganuma M. et al. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis 2014; 8: 1444-1453
    CrossrefPubMedGoogle Scholar
  • 21 Watanabe M, Nishino H, Sameshima Y. et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. Aliment Pharmacol Ther 2013; 38: 264-273
    CrossrefPubMedGoogle Scholar
  • 22 d’Albasio G, Pacini F, Camarri E. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-1147
    PubMedGoogle Scholar
  • 23 Yokoyama H, Takagi S, Kuriyama S. et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-1120
    CrossrefPubMedGoogle Scholar
  • 24 Kruis W, Jonaitis L, Pokrotnieks J. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-322
    CrossrefPubMedGoogle Scholar
  • 25 Yokoyama H, Takagi S, Kuriyama S. et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-1120
    CrossrefPubMedGoogle Scholar
  • 26 Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?. Inflamm Bowel Dis 2008; 14 (Suppl. 02) S238-S239
    CrossrefPubMedGoogle Scholar
  • 27 Heap GA, So K, Weedon M. et al. Clinical Features and HLA Association of 5-Aminosalizylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 149-158
    CrossrefPubMedGoogle Scholar
  • 28 Zallot C, Billioud V, Frimat L. et al. 5-Aminosalizylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. J Crohns Colitis 2013; 7: 551-555
    CrossrefPubMedGoogle Scholar
  • 29 Nikolaus S, Schreiber S, Siegmund B. et al. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. J Crohns Colitis 2017; 11: 1052-1062
    CrossrefPubMedGoogle Scholar
  • 30 Losurdo G, Iannone A, Contaldo A. et al. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2015; 24: 499-505
    CrossrefPubMedGoogle Scholar
  • 31 Lindgren SC, Flood LM, Kilander AF. et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835
    CrossrefPubMedGoogle Scholar
  • 32 Llao J, Naves JE, Ruiz-Cerulla A. et al. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. J Crohns Colitis 2014; 8: 1523-1528
    CrossrefPubMedGoogle Scholar
  • 33 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
    CrossrefPubMedGoogle Scholar
  • 34 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265 e1–e3
    CrossrefPubMedGoogle Scholar
  • 35 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95; quiz e14–e5
    CrossrefPubMedGoogle Scholar
  • 36 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109 e1
    CrossrefPubMedGoogle Scholar
  • 37 Lennard-Jones JE, Ritchie JK, Hilder W. et al. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-584
    CrossrefPubMedGoogle Scholar
  • 38 Travis SP, Farrant JM, Ricketts C. et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910
    CrossrefPubMedGoogle Scholar
  • 39 Benazzato L, D’Inca R, Grigoletto F. et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 36: 461-466
    CrossrefPubMedGoogle Scholar
  • 40 Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut 1991; 32: 1535-1537
    CrossrefPubMedGoogle Scholar
  • 41 Carbonnel F, Gargouri D, Lemann M. et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279
    CrossrefPubMedGoogle Scholar
  • 42 Carbonnel F, Lavergne A, Lemann M. et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550-1557
    CrossrefPubMedGoogle Scholar
  • 43 Corte C, Fernandopulle N, Catuneanu AM. et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9: 376-381
    CrossrefPubMedGoogle Scholar
  • 44 Ho GT, Mowat C, Goddard CJ. et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-1087
    CrossrefPubMedGoogle Scholar
  • 45 Kato K, Ohkusa T, Terao S. et al. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther 2014; 39: 949-956
    CrossrefPubMedGoogle Scholar
  • 46 Mantzaris GJ, Hatzis A, Kontogiannis P. et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46
    PubMedGoogle Scholar
  • 47 Lichtiger S, Present DH, Kornbluth A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
    CrossrefPubMedGoogle Scholar
  • 48 D’Haens G, Lemmens L, Geboes K. et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329
    CrossrefPubMedGoogle Scholar
  • 49 Van Assche G, D’Haens G, Noman M. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
    CrossrefPubMedGoogle Scholar
  • 50 Laharie D, Bourreille A, Branche J. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
    CrossrefPubMedGoogle Scholar
  • 51 Williams JG, Alam MF, Alrubaiy L. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016; 1: 15-24
    CrossrefPubMedGoogle Scholar
  • 52 Shibolet O, Regushevskaya E, Brezis M. et al Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005:CD004277
    PubMedGoogle Scholar
  • 53 Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592
    CrossrefPubMedGoogle Scholar
  • 54 Moskovitz DN, Van Assche G, Maenhout B. et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765
    CrossrefPubMedGoogle Scholar
  • 55 Bamba S, Tsujikawa T, Inatomi O. et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 494-498
    CrossrefPubMedGoogle Scholar
  • 56 Walch A, Meshkat M, Vogelsang H. et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010; 4: 398-404
    CrossrefPubMedGoogle Scholar
  • 57 Cheifetz AS, Stern J, Garud S. et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol 2011; 45: 107-112
    CrossrefPubMedGoogle Scholar
  • 58 Ogata H, Matsui T, Nakamura M. et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262
    CrossrefPubMedGoogle Scholar
  • 59 Ogata H, Kato J, Hirai F. et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-808
    CrossrefPubMedGoogle Scholar
  • 60 Komaki Y, Komaki F, Ido A. et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis 2016; 10: 484-494
    CrossrefPubMedGoogle Scholar
  • 61 Schmidt KJ, Herrlinger KR, Emmrich J. et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis – experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-136
    CrossrefPubMedGoogle Scholar
  • 62 Yamamoto T, Shimoyama T, Umegae S. et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Aliment Pharmacol Ther 2016; 43: 705-716
    CrossrefPubMedGoogle Scholar
  • 63 Sandborn WJ, Su C, Sands BE. et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine 2017; 376: 1723-1736
    CrossrefPubMedGoogle Scholar
  • 64 Panés J, Vermeire S, Lindsay JO. et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. Journal of Crohn’s and Colitis 2018; 13: 139-140
    CrossrefPubMedGoogle Scholar
  • 65 Jarnerot G, Hertervig E, Friis-Liby I. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811
    CrossrefPubMedGoogle Scholar
  • 66 Gustavsson A, Jarnerot G, Hertervig E. et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984-989
    CrossrefPubMedGoogle Scholar
  • 67 Sjoberg M, Magnuson A, Bjork J. et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377-387
    CrossrefPubMedGoogle Scholar
  • 68 Monterubbianesi R, Aratari A, Armuzzi A. et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014; 8: 852-858
    CrossrefPubMedGoogle Scholar
  • 69 Mortensen C, Caspersen S, Christensen NL. et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis 2011; 5: 28-33
    CrossrefPubMedGoogle Scholar
  • 70 Brandse JF, Mathot RA, van der Kleij D. et al. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14: 251-258 e1–e2
    CrossrefPubMedGoogle Scholar
  • 71 Brandse JF, van den Brink GR, Wildenberg ME. et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015; 149: 350-355 e2
    CrossrefPubMedGoogle Scholar
  • 72 Gibson DJ, Heetun ZS, Redmond CE. et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335 e1
    CrossrefPubMedGoogle Scholar
  • 73 Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013; 28: 287-293
    CrossrefPubMedGoogle Scholar
  • 74 Lowenberg M, Duijvis NW, Ponsioen C. et al. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol 2014; 26: 1240-1246
    CrossrefPubMedGoogle Scholar
  • 75 Hyde GM, Jewell DP, Kettlewell MG. et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44: 1436-1440
    CrossrefPubMedGoogle Scholar
  • 76 Ferrante M, D’Hoore A, Vermeire S. et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1062-1070
    CrossrefPubMedGoogle Scholar
  • 77 Narula N, Fine M, Colombel JF. et al. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?. Inflamm Bowel Dis 2015; 21: 1683-1694
    CrossrefPubMedGoogle Scholar
  • 78 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663
    CrossrefPubMedGoogle Scholar
  • 79 Kappelman MD, Horvath-Puho E, Sandler RS. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943
    CrossrefPubMedGoogle Scholar
  • 80 Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003; 98: 2363-2371
    CrossrefPubMedGoogle Scholar
  • 81 Hebden JM, Blackshaw PE, Perkins AC. et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 155-161
    CrossrefPubMedGoogle Scholar
  • 82 Nel JA. [Management of patients with AMS 800 urinary artificial sphincter]. Nurs RSA 1991; 6: 28-32
    PubMedGoogle Scholar
  • 83 Sandborn WJ, Tremaine WJ, Schroeder KW. et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429-1435
    CrossrefPubMedGoogle Scholar
  • 84 Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 2254-2259
    CrossrefPubMedGoogle Scholar
  • 85 van Dieren JM, van Bodegraven AA, Kuipers EJ. et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009; 15: 193-198
    CrossrefPubMedGoogle Scholar
  • 86 Carbonnel F, Boruchowicz A, Duclos B. et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-2476
    CrossrefPubMedGoogle Scholar
  • 87 Actis GC, Fadda M, David E. et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13
    CrossrefPubMedGoogle Scholar
  • 88 Szanto K, Molnar T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohns Colitis 2018; 12: 629
    CrossrefPubMedGoogle Scholar
  • 89 Sandborn WJ, Panes J, D’Haens GR. et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2019; 17: 1541-1550
    CrossrefPubMedGoogle Scholar
  • 90 Ardizzone S, Maconi G, Russo A. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
    CrossrefPubMedGoogle Scholar
  • 91 Chebli LA, Chaves LD, Pimentel FF. et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16: 613-619
    CrossrefPubMedGoogle Scholar
  • 92 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400 e3
    CrossrefPubMedGoogle Scholar
  • 93 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
    CrossrefPubMedGoogle Scholar
  • 94 Carbonnel F, Colombel JF, Filippi J. et al. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology 2016; 150: 380-388 e4
    CrossrefPubMedGoogle Scholar
  • 95 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD005112
    PubMedGoogle Scholar
  • 96 Reinisch W, Sandborn WJ, Hommes DW. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787
    CrossrefPubMedGoogle Scholar
  • 97 Reinisch W, Sandborn WJ, Panaccione R. et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19: 1700-1709
    CrossrefPubMedGoogle Scholar
  • 98 Gies N, Kroeker KI, Wong K. et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-528
    CrossrefPubMedGoogle Scholar
  • 99 Colombel JF, Sandborn WJ, Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
    CrossrefPubMedGoogle Scholar
  • 100 van Schaik T, Maljaars JP, Roopram RK. et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis 2014; 20: 2292-2298
    CrossrefPubMedGoogle Scholar
  • 101 Benson A, Barrett T, Sparberg M. et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12
    CrossrefPubMedGoogle Scholar
  • 102 Yamamoto S, Nakase H, Mikami S. et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-597
    CrossrefPubMedGoogle Scholar
  • 103 Gisbert JP, Marin AC, McNicholl AG. et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613-623
    CrossrefPubMedGoogle Scholar
  • 104 Baumgart DC, Bokemeyer B, Drabik A. et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-1102
    CrossrefPubMedGoogle Scholar
  • 105 Sandborn WS, D’Haens G. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology 2016; 150: S157
    CrossrefPubMedGoogle Scholar
  • 106 Ferrante M, Vermeire S, Fidder H. et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225
    CrossrefPubMedGoogle Scholar
  • 107 Feagan BG, Sandborn WJ, Lazar A. et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-118 e3
    CrossrefPubMedGoogle Scholar
  • 108 Colombel JF, Sandborn WJ, Ghosh S. et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014; 109: 1771-1780
    CrossrefPubMedGoogle Scholar
  • 109 Loftus Jr EV, Colombel JF, Feagan BG. et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis 2017; 11: 400-411
    PubMedGoogle Scholar
  • 110 Feagan BG, Rubin DT, Danese S. et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol 2017; 15: 229-239 e5
    CrossrefPubMedGoogle Scholar
  • 111 Noman M, Ferrante M, Bisschops R. et al. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis 2017; 11: 1085-1089
    CrossrefPubMedGoogle Scholar
  • 112 Stallmach A, Langbein C, Atreya R. et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther 2016; 44: 1199-1212
    CrossrefPubMedGoogle Scholar
  • 113 Amiot A, Serrero M, Peyrin-Biroulet L. et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther 2017; 46: 310-321
    CrossrefPubMedGoogle Scholar
  • 114 Bickston SJ, Behm BW, Tsoulis DJ. et al Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2014:CD007571
    PubMedGoogle Scholar
  • 115 Ungar B, Kopylov U, Engel T. et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2017; 45: 276-282
    CrossrefPubMedGoogle Scholar
  • 116 Matsumoto T, Motoya S, Watanabe K. et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial. J Crohns Colitis 2016; 10: 1259-1266
    CrossrefPubMedGoogle Scholar
  • 117 Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
    CrossrefPubMedGoogle Scholar
  • 118 Gisbert JP, Marin AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016; 111: 632-647
    CrossrefPubMedGoogle Scholar
  • 119 Torres J, Boyapati RK, Kennedy NA. et al. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149: 1716-1730
    CrossrefPubMedGoogle Scholar